Yi-Ching Wang
王憶卿 講座教授
Yi-Ching Wang, PhD 王憶卿 教授
Dr. Yi-Ching Wang received her PhD in Genetics from Michigan State University, USA in 1993. She returned to Taiwan to join the Institute of Biomedical Sciences at Academia Sinica for post-doctoral training. Dr. Wang became an associated professor at Institute of Toxicology in Chung Shan Medical University in 1995. She then joined the Department of Life Science in National Taiwan Normal University and was promoted to professor in 1999. In 2006, Dr. Wang moved to the Department of Pharmacology, College of Medicine, National Cheng Kung University, where she served as Distinguished Professor until 2015 when she took up the current position as a Chair Professor at the same university.
As a Principal Investigator for the last 30 years, Dr. Yi-Ching Wang has published nearly 150 SCI papers [including prestigious journals such as Journal of Clinical Oncology, Journal of Clinical Investigation, Nature Communications, Advced Functional Materials, Nucleic Acids Research, Journal of Thoracic Oncology, Cancer Research, Clinical Cancer Research] on lung cancer and esophageal cancer with H-index of 46. In addition, her group has reported more than 300 conference papers, 4 book chapters, and obtained 4 Taiwan patents and 1 US patent (2 in application).
Dr. Yi-Ching Wang's laboratory has a long-standing research interest on the molecular mechanisms involved in tumorigenesis. Dr. Wang's group investigates the etiological association of alterations in tumor suppressor genes and oncogenes in cancer signaling. Dr. Wang has continued to do research on cancer genomics and epigenomics of DNA methylation and chromatin alteration profiles for identification of new genes critical to lung tumorigenesis. More recently, Dr. Wang's team investigates the underlying mechanisms of NRF2 antioxidant transcription factor in cancer progression and drug resistance. In addition, Dr. Wang focuses on the role of Rab37 small GTPase in the regulation of exocytosis and malfunction of Rab37 in tumorigenesis and tumor microenvironment. Several potential anti-cancer drugs and immunomodulation antibodies are under development in her laboratory.
Research Interests
- Cancer biology and molecular medicine
- Vesicle trafficking and tumor microenvironment
- Transcription regulation and cell signaling
- Epigenetics and epigenomics
- Anticancer drug/antibody development
Education and Experience
- 1993 PhD, Genetics, Michigan State University
- 1995 Associate Professor, Molecular Toxicology, Chung Shan Medical University
- 1999 Professor, Life Science, National Taiwan Normal University
- 2006 Distinguished Professor, Pharmacology, National Cheng Kung University
- 2015 Chair Professor, Pharmacology, National Cheng Kung University
- 2015-2018 President, The Taiwan Society For Biochemistry And Molecular Biology
Honors / Awards
2022
- 66th Academic Award of Ministry of Education 第66屆教育部學術獎
2021-2023
- The Foundation for the Advancement of Outstanding Scholarship Award 傑出人才基金會傑出人才講座
2018
- K.T. Li Honorary Scholar Award, Taiwan 李國鼎科技與人文講座榮譽學者獎
2017
- Dr. Wang Min-Ning Memory Foundation for Excellent Basic Medical Research award, Taiwan 財團法人王民寧先生紀念基金會【基礎醫學類】傑出貢獻獎
2017~2023
- Merit MOST Research Fellow Award, Taiwan科技部特約研究
2013
- Dr. Tung Ta-Cheng Memorial Award for Basic Cancer Research, Chinese Oncology Society, Taiwan 董大成博士癌症基礎醫學研究傑出獎
2008
- Outstanding research award, Pharmacology Society, Taiwan藥理學會傑出研究獎
2007
- Distinguished alumnus of Chinese Culture University, Taiwan 文化大學傑出校友
2004, 2010, 2014
- MOST Excellent Research Award, Taiwan 科技部傑出研究獎
Publications
